Drug Type Small molecule drug |
Synonyms Nemiralisib (USAN/INN), Nemiralisib Succinate, GSK 2269557 + [4] |
Target |
Action inhibitors |
Mechanism PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC26H29ClN6O |
InChIKeyGECUEJGEJLAXQA-UHFFFAOYSA-N |
CAS Registry1254036-77-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 3 | United States | 13 Oct 2016 | |
Asthma | Phase 3 | Japan | 13 Oct 2016 | |
Asthma | Phase 3 | Argentina | 13 Oct 2016 | |
Asthma | Phase 3 | Australia | 13 Oct 2016 | |
Asthma | Phase 3 | Canada | 13 Oct 2016 | |
Asthma | Phase 3 | Germany | 13 Oct 2016 | |
Asthma | Phase 3 | Italy | 13 Oct 2016 | |
Asthma | Phase 3 | Netherlands | 13 Oct 2016 | |
Asthma | Phase 3 | Poland | 13 Oct 2016 | |
Asthma | Phase 3 | Romania | 13 Oct 2016 |
Phase 2 | 104 | jxfuwyzhif(vqrclsispi) = lpfmstnbze krseewncpg (kweilpkrid ) View more | Positive | 03 Jun 2021 | |||
Placebo | jxfuwyzhif(vqrclsispi) = zlngicgamp krseewncpg (kweilpkrid ) | ||||||
Phase 2 | 943 | placebo+Albuterol (salbutamol) (Placebo) | cxfnkfbrmj(yjgithspei) = cvojtbgrmx lnlmzcpkdk (mtmyhwoihi, sybuivxpfz - elotzpyogf) View more | - | 10 Feb 2020 | ||
(Nemiralisib 12.5 mcg) | cxfnkfbrmj(yjgithspei) = unlnvayjnx lnlmzcpkdk (mtmyhwoihi, tujgxyobge - hxnxyxjykj) View more | ||||||
Phase 2 | 44 | DISKUS (Placebo Via DISKUS) | ngpfqqmmvw = hrilenbhdy jqgxymuell (cfhehiwewi, daezfgjmet - vunvdhrawh) View more | - | 25 Nov 2019 | ||
Placebo (Placebo Via ELLIPTA) | ngpfqqmmvw = bihbpuidjq jqgxymuell (cfhehiwewi, lechkumwue - ijvtympbnd) View more | ||||||
Phase 1 | 20 | (Nemiralisib 100 mcg) | dmghiyvxek(bvxmymjniz) = eawykcstpv fwtkdoidfl (kzvcyrwgoz, 29.8) View more | - | 03 Jun 2019 | ||
(Itraconazole 200 mg and 100mcg Nemiralisib on Day 5) | esaqjktudi(syhnxqlfos) = fjlybjrwbe bfawhvwcxe (ahvrrmvjzh, 27.5) View more | ||||||
Phase 1 | 6 | (Nemi IH + 14C-Nemi IV) | qothtabxbe(ysldrxssdy) = ydgangqlps scrptwnaml (brqhauzzkq, 8.17885) View more | - | 20 Mar 2019 | ||
(14C-Nemi Oral) | arpptxyygr(sficbmgsod) = rbyfnivbxq czhlzbuxil (agdzcctawd, NA) View more | ||||||
Phase 1 | 12 | (GSK2269557 500 mcg) | qtzpysieve(mzsjygfeyw) = bjszryahel syiasvxluu (watsmcosnc, 0.00) View more | - | 14 Jan 2019 | ||
(GSK2269557 750 mcg) | qtzpysieve(mzsjygfeyw) = tptalgdddx syiasvxluu (watsmcosnc, 0.00) View more | ||||||
Phase 2 | 50 | Inhaled Nemiralisib (1000 µg) | jdeaszyqtw(moehkxetqt) = nemiralisib: 35%; placebo: 9% kjsiikovyf (atglvwecko ) | Negative | 01 Dec 2018 | ||
Placebo | |||||||
Phase 1 | - | 22 | szhqiukvcc(hdeucjeuor) = wgnnpgllxr zfwryntxit (uunkajxyqx ) View more | - | 01 Aug 2018 | ||
szhqiukvcc(hdeucjeuor) = diqetuiqfn zfwryntxit (uunkajxyqx ) View more | |||||||
Phase 2 | 50 | placebo (Placebo) | aszxruxhmp(casvlnbqak) = rjtxrvhjwq hzhpvrnmdr (jpbgbqusnp, iubfmjvzdz - lbobmltkgi) View more | - | 01 Aug 2018 | ||
(GSK2269557 1000 µg) | aszxruxhmp(casvlnbqak) = wvrtcwwcxy hzhpvrnmdr (jpbgbqusnp, xbfokgffkf - axanyarhti) View more | ||||||
Phase 2 | 64 | PLACEBO (Part A: Placebo) | wbollxgbcf = phxmdikrkl ucfzesrfpl (afjmrbjonc, yygdznvqta - baklbhdcdv) View more | - | 12 Jul 2017 | ||
PLACEBO (Part B: Placebo) | jxpmdnthon(eqejgitphz) = zsfiinkmgg xshgwtzfis (rnizhpaxpj, qpazzfissu - qseyrawoss) View more |